Loading...

Cerevel Therapeutics Holdings ($CERE)

Stock Image

CERE Overview

Cerevel Therapeutics Holdings operates as a clinical-stage biopharmaceutical company that engages in the development of various therapies for neuroscience diseases.It is developing CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase Ib multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase I proof-of-principle trial for acute anxiety.The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder.It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT Cerevel Therapeutics Holdings

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.